HUMA250117P4000
- 0.50
- -0.20-28.57%
Humacyte Newsroom
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
Humacyte Is Maintained at Buy by Benchmark
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $17
Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Ligand Pharma (LGND)
Express News | Humacyte Inc : Benchmark Raises Target Price to $17 From $15
12 Health Care Stocks Moving In Friday's Pre-Market Session
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $15
Aptose APTO NASDAQ Compliance; Humacyte HUMA Full Approval
Humacyte's Symvess Gains FDA Approval and Positions for Market Success
Humacyte HUMA Approval; Molecular MTEM Notice of Delisting
BTIG Sticks to Their Buy Rating for Humacyte (HUMA)
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
Mission Produce, Nvidia, Humacyte, BlackBerry And Other Big Stocks Moving Higher On Friday
Spotlight on Humacyte: Analyzing the Surge in Options Activity
Humacyte Is Maintained at Buy by D. Boral Capital
Humacyte Price Target Maintained With a $25.00/Share by D. Boral Capital
Wall Street Set to Open Lower Friday; Key Inflation Data Lower Than Expected
Express News | Humacyte Shares Are Trading Higher After the Company Announced FDA Approval for SYMVESS for Treating Extremity Vascular Injuries. HC Wainwright & Co. Raised Its Price Target on the Stock From $12 to $15